CD-70 CAR-NK

CD-70 CAR-NK is an allogeneic Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapeutic. It is designed to target the CD70 antigen, which is frequently overexpressed in various hematologic and solid tumors. This cell therapy leverages the precision targeting of a CAR, engineered to recognize CD70, combined with the innate cytotoxic mechanisms of Natural Killer (NK) cells. This approach aims to provide an "off-the-shelf" immunotherapy with potential advantages over CAR-T cells, such as a reduced risk of graft-versus-host disease (GvHD). The therapeutic is in preclinical and early-stage clinical development for multiple cancer indications. TC BioPharm is in the process of acquiring a proprietary manufacturing process for this therapeutic.